Chemical Component Summary

NameTAXOTERE
Identifiersn/a
FormulaC43 H53 N O14
Molecular Weight807.88
TypeNON-POLYMER
Isomeric SMILESCC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](c5ccccc5)NC(=O)OC(C)(C)C)O)O)OC(=O)c6ccccc6)(CO4)OC(=O)C)O)C)O
InChIInChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
InChIKeyZDZOTLJHXYCWBA-VCVYQWHSSA-N

Chemical Details

Formal Charge0
Atom Count111
Chiral Atom Count11
Bond Count116
Aromatic Bond Count12

Drug Info: DrugBank

DrugBank IDDB01248 
NameDocetaxel
Groups
  • approved
  • investigational
DescriptionDocetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel reversibly binds to tubulin with high affinity in a 1:1 stoichiometric ratio
Synonyms
  • N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
  • N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
  • Docetaxel
  • Docetaxel trihydrate
  • Docetaxel anhydrous
Brand Names
  • Docetaxel
  • Docetaxel Anhydrous
  • Docetaxel anhydrous
  • Docetaxel Non-Alcohol Formula
  • Docetaxel Winthrop
IndicationFor the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
Categories
  • Agents Causing Muscle Toxicity
  • Antimitotic Agents
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • BCRP/ABCG2 Substrates
ATC-CodeL01CD02
CAS number114977-28-5

Drug Targets

NameTarget SequencePharmacological ActionActions
Tubulin beta-1 chainMREIVHIQIGQCGNQIGAKFWEMIGEEHGIDLAGSDRGASALQLERISVY...unknown
Apoptosis regulator Bcl-2MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFS...unknown
Microtubule-associated protein 2MADERKDEAKAPHWTSAPLTEASAHSHPPEIKDQGGAGEGLVRSANGFPY...unknown
Microtubule-associated protein 4MADLSLADALTEPSPDIEGEIKRDFIATLEAEAFDDVVGETVGKTDYIPL...unknown
Microtubule-associated protein tauMAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQT...unknown
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem148124
ChEBICHEBI:4672
ChEMBLCHEMBL92
PharosCHEMBL92